IE
ALLO icon

Israel Englander’s Allogene Therapeutics ALLO Stock Holding History

Israel Englander’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1M Buy
4,843,889
+1,521,836
+46% +$3.34M ﹤0.01% 2269
2026
Q1 		$8.11M Buy
3,322,053
+1,480,746
+80% +$2.97M ﹤0.01% 2387
2025
Q4 		$2.52M Sell
1,841,307
-1,548,719
-46% -$2.04M ﹤0.01% 3736
2025
Q3 		$4.2M Buy
3,390,026
+1,887,302
+126% +$2.25M ﹤0.01% 3324
2025
Q2 		$1.7M Buy
1,502,724
+1,245,875
+485% +$1.66M ﹤0.01% 4019
2025
Q1 		$375K Buy
+256,849
New +$484K ﹤0.01% 4980
2024
Q4 		– Sell
-258,002
Closed -$722K – 5914
2024
Q3 		$722K Buy
258,002
+78,378
+44% +$209K ﹤0.01% 4535
2024
Q2 		$419K Sell
179,624
-21,846
-11% -$64.4K ﹤0.01% 4710
2024
Q1 		$901K Sell
201,470
-1,717,544
-90% -$7.17M ﹤0.01% 4383
2023
Q4 		$6.16M Buy
1,919,014
+1,794,616
+1,443% +$5.09M ﹤0.01% 2613
2023
Q3 		$394K Sell
124,398
-85,368
-41% -$374K ﹤0.01% 4785
2023
Q2 		$1.04M Sell
209,766
-793,230
-79% -$4.29M ﹤0.01% 4010
2023
Q1 		$4.96M Sell
1,002,996
-2,272,128
-69% -$14.6M ﹤0.01% 2609
2022
Q4 		$20.6M Buy
3,275,124
+1,878,645
+135% +$17.4M 0.01% 1423
2022
Q3 		$15.1M Buy
1,396,479
+619,607
+80% +$8.42M 0.01% 1640
2022
Q2 		$8.86M Buy
776,872
+205,666
+36% +$1.83M 0.01% 2191
2022
Q1 		$5.2M Buy
571,206
+416,173
+268% +$4.33M ﹤0.01% 2889
2021
Q4 		$2.31M Sell
155,033
-73,590
-32% -$1.3M ﹤0.01% 3642
2021
Q3 		$5.88M Sell
228,623
-276,672
-55% -$6.57M ﹤0.01% 2680
2021
Q2 		$13.2M Buy
505,295
+222,330
+79% +$6.34M 0.01% 1591
2021
Q1 		$9.99M Sell
282,965
-142,517
-33% -$4.81M 0.01% 1777
2020
Q4 		$10.7M Buy
425,482
+357,234
+523% +$11.6M 0.01% 1651
2020
Q3 		$2.57K Sell
68,248
-138,931
-67% -$5.24M ﹤0.01% 2403
2020
Q2 		$8.87M Buy
207,179
+155,678
+302% +$5.63M 0.01% 1301
2020
Q1 		$1M Sell
51,501
-20,392
-28% -$486K ﹤0.01% 2464
2019
Q4 		$1.87M Buy
+71,893
New +$1.98M ﹤0.01% 2662

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Israel Englander's ALLO Position: Q2 2026 in Review

Israel Englander increased its Allogene Therapeutics (ALLO) stake by 46% in Q2 2026, buying an estimated $3.34M and bringing the position to 4,843,889 shares worth $10.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2269.

Israel Englander first reported a position in ALLO in Q4 2019 and has held it in 26 quarters since. The position peaked at $20.6M in Q4 2022. 208 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Israel Englander held 4,843,889 shares of Allogene Therapeutics worth $10.1M as of Q2 2026.
  • Israel Englander bought 1,521,836 Allogene Therapeutics shares in Q2 2026, an estimated $3.34M.
  • Allogene Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2269 holding.
  • Israel Englander first reported a position in Allogene Therapeutics in Q4 2019 and has held it in 26 quarters since.
  • Israel Englander's Allogene Therapeutics position peaked at $20.6M in Q4 2022.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.